Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Lipid Metabolism

Background:

• Dyslipidemia, characterized by abnormal blood lipid levels, is a major risk factor for cardiovascular diseases.
• Current hypolipidemic agents have limitations, necessitating the development of novel therapeutic strategies.
• The phenylenebis(oxy)bis[2,2-dimethylpentanoic acid] scaffold represents a potential area for new drug discovery.

Purpose of the Study:

• To synthesize and evaluate a series of phenylenebis(oxy)bis[2,2-dimethylpentanoic acid] derivatives as potential hypolipidemic agents.
• To identify the most potent compound within this series for further investigation.
• To compare the efficacy of the lead compound against a known hypolipidemic drug, gemfibrozil.

Main Methods:

• Chemical synthesis of a series of phenylenebis(oxy)bis[2,2-dimethylpentanoic acid] compounds.
• In vivo evaluation of hypolipidemic activity in a rat model.
• Comparative pharmacokinetic and pharmacodynamic studies with gemfibrozil.

Main Results:

• Compound 18 (CI-924) emerged as the most potent hypolipidemic agent in the synthesized series.
• CI-924 demonstrated a dual action, reducing low-density lipoprotein cholesterol and increasing high-density lipoprotein (HDL) cholesterol in rats.
• CI-924 achieved equivalent HDL cholesterol elevation at one-third the dose of gemfibrozil.

Conclusions:

• The phenylenebis(oxy)bis[2,2-dimethylpentanoic acid] series, particularly CI-924, holds significant potential as a novel hypolipidemic therapy.
• CI-924 exhibits a favorable efficacy profile compared to gemfibrozil, suggesting improved therapeutic potential.
• Further research into structure-activity relationships can optimize CI-924 for clinical application.